Rivaroxaban Vote

The US Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of Rivaroxaban (Xarelto) oral anti-Xa antithrombotic for prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip replacement or knee replacement surgery. The FDA has until May 28 to vote full approval. See Medical News Today for more information.